Bayesian decision procedures for binary and continuous bivariate dose-escalation studies

Pharmaceutical Statistics

Volumn 5, Issue 2, 2006, Pages 125-133

  Zhou, Yinghui ^a   Whitehead, John ^a   Bonvini, Elisa ^a   Stevens, John W ^b  

^a UNIVERSITY OF READING   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Bayesian decision procedure; Dose escalation; Linear regression; Logistic regression; Phase I clinical trial

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CYTOSTATIC AGENT; CYTOTOXIC AGENT; LEUKOTRIENE B4 DERIVATIVE;

ARTICLE; BAYES THEOREM; CANCER; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG SAFETY; HUMAN; LINEAR REGRESSION ANALYSIS; LOGISTIC REGRESSION ANALYSIS; MATHEMATICAL COMPUTING; PNEUMONIA; PROBABILITY; STATISTICAL MODEL; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

BAYES THEOREM; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; REGRESSION ANALYSIS;

EID: 33745176255     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.222     Document Type: Article

References (22)

1. Edler L. Overview of phase I trials. In Handbook of statistics in clinical oncology, Crowley J (ed.). Marcel Dekker: New York, 2001; pp. 1-34.
2. O'Quigley J. Dose-finding designs using continual reassessment method. In Handbook of statistics in clinical oncology, Crowley J (ed.). Marcel Dekker: New York, 2001; pp. 35-72.
3. Whitehead J, Zhou Y, Stallard N, Todd S, Whitehead A. Learning from previous responses in phase I dose-escalation studies. British Journal of Clinical Pharmacology 2001; 52:1-7.
4. Rosenberger WF, Haines LM. Competing designs for phase I clinical trials: a review. Statistics in Medicine 2002; 21:2757-2770.
5. Zhou Y. Choice of designs and doses for early phase trials. Fundamental and Clinical Pharmacology 2004; 18:373-378.
6. O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase I clinical trials in cancer. Biometrics 1990; 46:33-48.
7. Whitehead J, Williamson D. An evaluation of Bayesian decision procedures for dose-finding studies. Journal of Biopharmaceutical Medicine 1998; 8:445-467.
8. Cancer Research UK website, http://www.cancer-help.org.uk/help/ default.asp?page=5078
9. Gooley TA, Martin PJ, Fisher LD, Pettinger M. Simulation as a design tool for phase I/II clinical trials: an example from bone-marrow transplantation. Controlled Clinical Trials 1994; 15:450-462.
10. Thall PF, Russell KE. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. Biometrics 1998; 54:251-264.
11. O'Quigley J, Hughes MD, Fenton T. Dose-finding designs for HIV studies. Biometrics 2001; 57: 1018-1029.
12. Ishizuka N, Ohashi Y. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Statistics in Medicine 2001; 20:2661-2681.
13. Braun TM. The bivariate continual reassessment method: extending the CRM to phase I trials of two competing outcomes. Controlled Clinical Trials 2002; 23:240-256.
14. Loke YC, Tan SB, Cai Y, Machin D. A Bayesian dose finding design for dual endpoint phase I trials. Statistics in Medicine 2006; 25:3-22.
15. Whitehead J, Zhou Y, Stevens J, Blakey G, Price J, Leadbetter J. Bayesian decision procedures for dose-escalation based on evidence of undesirable events and therapeutic benefit. Statistics in Medicine 2006; 25:37-53.
16. Whitehead J, Zhou Y, Stevens J, Blakey G. An evaluation of a Bayesian method of dose-escalation based on bivariate binary responses. Journal of Biopharmaceutical Statistics 2004; 14:969-983.
17. Patterson S, Francis S, Ireson M, Webber D, Whitehead J. A novel Bayesian decision procedure for early phase dose finding studies. Journal of Biopharmaceutical Statistics 1999; 9:583-597.
18. Whitehead J, Zhou Y, Patterson S, Webber D, Francis S. Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers. Biostatistics 2001; 2:47-61.
19. Whitehead J, Zhou Y, Mander A, Ritchie S, Sabin A, Wright A. An evaluation of Bayesian designs for dose-escalation studies in healthy volunteers. Statistics in Medicine 2006; 25:433-445.
20. Tsutakawa RK. Bayesian inference for bioassay. Technical Report 52, Mathematical Sciences, University of Missouri, Columbia, 1975.
21. West M, Harrison PJ. Bayesian forecasting and dynamic models. Springer: New York, NY 1997.
22. Hahn ED. Re-examining informative prior elicitation through the lens of Markov chain Monte Carlo methods. Journal of the Royal Statistical Society, Series A 2006; 169:37-48.